Volume 1.44 | Nov 15

Hematopoiesis News 1.44, November 15, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


mTOR Activation Induces Tumor Suppressors that Inhibit Leukemogenesis and Deplete Hematopoietic Stem Cells after Pten Deletion  ShareThis
Researchers found that the depletion of Pten-deficient hematopoietic stem cells (HSCs) was not caused by oxidative stress and could not be blocked by N-acetyl-cysteine. Instead, Pten deletion induced, and rapamycin attenuated, the expression of p16(Ink4a) and p53 in HSCs, and p19(Arf) and p53 in other hematopoietic cells. [Cell Stem Cell]



Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]

Follow us on Twitter! @Hema_News


Researchers Discover Key Mutation in Acute Myeloid Leukemia
Researchers have discovered mutations in a particular gene that affects the treatment prognosis for some patients with acute myeloid leukemia. [Press release from the National Institutes of Health discussing online prepublication in The New England Journal of Medicine]

Arsenic Early in Treatment Improves Survival for Leukemia Patients
Arsenic has a significant positive effect on the survival of patients with acute promyelocytic leukemia, when administered after standard initial treatment, according to a new, multi-center study. [Press release from the Wake Forest University Baptist Medical Center discussing online prepublication in Blood]

Mathematical Model of Red Blood Cells May Predict Risk of Anemia
A collaboration between a physician-researcher at Massachusetts General Hospital and a mathematician from Harvard University has led to development of a mathematical model reflecting how red blood cells change in size and hemoglobin content during their four-month lifespan. [Press release from Harvard School of Engineering and Applied Science discussing online prepublication in the Proceedings of the National Academy of Sciences USA]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Mdm2 Is Required for Survival of Hematopoietic Stem Cells/Progenitors Via Dampening of ROS-Induced p53 Activity
In the absence of Mdm2, stable p53R172P induced reactive oxygen species and cell cycle arrest, senescence, and cell death in the hematopoietic compartment. [Cell Stem Cell]

The Orphan Nuclear Receptor Nurr1 Restricts the Proliferation of Hematopoietic Stem Cells
The findings provide critical insight into the transcriptional control mechanisms that determine whether hematopoietic stem cells remain dormant or enter the cell cycle and begin to proliferate. [Nat Cell Biol]

Cannabinoid Receptor 2 and its Agonists Mediate Hematopoiesis and Hematopoietic Stem and Progenitor Cell Mobilization
Here, researchers show that bone marrow stromal cells express endocannabinoids (anandamide and 2-arachidonylglycerol), while CB2 receptors are expressed in human and murine hematopoietic stem and progenitor cells. [Blood]

Pharmacologic Modulation of the Calcium-Sensing Receptor Enhances Hematopoietic Stem Cell Lodgment in the Adult Bone Marrow
Using a calcium-sensing receptor (CaR) agonist, Cinacalcet, researchers assessed the effects of stimulating the CaR on the function of murine hematopoietic stem cells. [Blood]

Structure of the Leukemia Oncogene LMO2: Implications for the Assembly of a Hematopoietic Transcription Factor Complex
The results together with molecular docking and analysis of evolutionarily conserved residues yield the first structural model of the DNA binding complex containing LMO2, LDB1, SCL/TAL1 and GATA-1. [Blood]

PD-L1 Blockade Effectively Restores Strong Graft-Versus-Leukemia Effects Without Graft-Versus-Host-Disease After Delayed Adoptive Transfer of T Cell Receptor Gene-Engineered Allogeneic CD8+ T Cells
Researchers investigated whether the use of MHC-mismatched T cells would prolong the in vivo persistence of tumor-reactive T cell receptor gene expressing T cells by continuous antigen-driven proliferation via the endogenous potentially alloreactive receptor. [Blood]

Building Multifunctionality Into a Complex Containing Master Regulators of Hematopoiesis
The demonstration that non-DNA binding components ETO2 and LIM domain protein LMO2 exert qualitatively distinct functions at endogenous loci illustrates how components of complexes containing master developmental regulators can impart the capacity to regulate unique cohorts of target genes, thereby diversifying complex function. [Proc Natl Acad Sci USA]

Physiological and Pathological Population Dynamics of Circulating Human Red Blood Cells
Researchers used theory from statistical physics and data from the hospital clinical laboratory [d’Onofrio G, et al. (1995) Blood 85:818-823] to develop a master equation model for red blood cell maturation and clearance. [Proc Natl Acad Sci USA]

The E2A-HLF Oncogenic Fusion Protein Acts Through Lmo2 and Bcl-2 to Immortalize Hematopoietic Progenitors
The oncogenic fusion protein E2A-HLF is a chimeric transcription factor that arises from the t(17;19) translocation in childhood B cell acute lymphoblastic leukemias and is associated with very poor outcome. Researchers show that retroviral-mediated expression of E2A-HLF alone is sufficient to immortalize primary lymphoid progenitors. [Leukemia]


Immunosuppressive CD14(+)HLA-DR(low/neg) Monocytes in B Cell Non-Hodgkin’s Lymphoma
Researchers examined the immunophenotype of 40 non-Hodgkin’s lymphoma patients and 27 age-matched controls to better understand systemic immune suppression. [Blood]

The Different Extent of B and T Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapies in SCID Patients with Adenosine Deaminase Deficiency
The mobilization of T cell receptor excision circle+ cells, though lower than in controls, was stable with time after hematopoietic stem cell transplantation treatment, leading to a constant peripheral T cell number and to the diversification of the T cell repertoire; however, it was compromised in children receiving prolonged enzyme replacement therapy with pegylated bovine adenosine deaminase, whose T cells showed progressively narrowing T cell repertoires. [ J Immunol]



Cerus Corporation Prices Public Offering of Common Stock and Warrants
Cerus Corporation announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. [Cerus Corporation Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS (Listed by Date)

9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
November 17-19, 2010
Sonoma, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

NEW  The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada

Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States

Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States

Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States

Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Business Manager – Centre for Blood Cell Therapies (Cell Therapies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit  here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us